Rx Medicare

The U.S. Food and Drug Administration today approved Fluzone High-Dose, an inactivated influenza virus vaccine for people ages 65 years and older to prevent disease caused by influenza virus subtypes A and B. People in this age group are at highest risk for seasonal influenza complications, which may result in hospitalization and death…

Read More…

Related Posts

• Practice Fusion Identifies 300,000 High-Risk Patients For H1N1 Influenza Vaccine, In-line With CDC Pandemic Guidelines
• American Lung Association Supports Health Officials To Prevent The Spread Of Seasonal Influenza By Urging People To Get Vaccinated
• CSL Biotherapies Starts Shipment Of Seasonal Influenza Vaccine For The 2009-2010 Flu Season
• FDA Approves Vaccine For Seasonal Influenza
• NanoBio Initiates FDA Approved Clinical Trial For Adjuvanted Intranasal Influenza Vaccine
• Baxter Presents Clinical Efficacy Results From Phase III Study Of Seasonal Flu Vaccine
• AmpVacs A Broadly Protective Synthetic Influenza A Vaccine
• Dry Winters Linked To Seasonal Outbreaks Of Influenza
• As Influenza Cases Rise In Europe, Experts Urge Uptake Of H1N1 Vaccine
• Groups At High Risk Of H1N1 Influenza A Should Avoid Travelling To 2009 HAJJ
• FDA Approves Additional Vaccine For 2009 H1N1 Influenza Virus
• CSL Biotherapies Obtains FDA Licensure For Use Of Its Thimerosal-Free Pandemic Influenza A (H1N1) 2009 Monovalent Vaccine In Children
• Get Smart About Swine Flu H1N1 Swine Flu Vaccine Influenza P
• MANUFACTURING THE H1N1 FLU VACCINE NASAL SPRAY Influenza
• Influenza And H1N1: Alert For People With Lung Disease And Their Caregivers

Tags: ages, approved, dose, efficacy, high, influenza, intended, older, people, seasonal, specifically, vaccine

This entry was posted on Monday, December 28th, 2009 at 2:12 pm and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.